takeaways. and on key data some it resistance in the as Thank presented be a uproleselan E-selectin like begin relates extensive, by mechanism the I/II I'd as you, supporting underscoring Rachel. quite will AML. especially of that Phase to is data at the ASH of The abstract to
First, increased I/II the data from past extend the final It patients which provide the I'd patients for includes the in the NCI-sponsored survival the confidence time endpoints final database. key fewer locked GMI the data specified new includes now data follow-up initially with opted emphasize survival, our that to set amend that follow-up that like duration and set our Phase result of to from of in in a point We and the registration to protocol. underpin programs. protocol the to study includes data efficacy for is censored extended
the higher for data and cohorts our of response. MRD this remission bone on Over or marrow XX% between evaluable those diagnosed complete I'm Secondly, these the measurable micro would what disease, expect of of cohort in first in patients in to percentage achieved both see report MRD, of we exactly leukemic and be We stringent is negative. time pleased we to clinical a now relapsed/refractory who cell newly selectively this see achieve trial. we disease the uproleselan that patients level residual AML believe – as to present relationship each the disrupts environment. the –
with E-selectin blasts driver our both this combined expression, correlative improved with target lastly, data stem E-selectin Fred And binding data treated AML. is relapsed/refractory the can we and in that demonstrating poor leukemic E-selectin relevant, of MRD in expression show at we data levels higher disrupt negativity, underlying be population correlates survival blasts data, Hutchinson target, ligand on this correlating ligand ASH, support cohort the and resistance of These If Cancer cells on that on our Thirdly, with with cancer outcomes. expression response leukemic highly is clinical results of leukemic in with of will on at uproleselan. particularly on patients Center patient outcomes E-selectin to that collaborators the clinical cells hypothesis independent will in ligand also presenting this the expression believe a be AML. further
in that the E-selectin the set interesting in E-selectin potentially patients FLTX-mutated relapsed/refractory AML. of observation FLTX population, vascular the leukemic particularly with in resistance. factor Dr. sequestration is antitumor high-risk chemotherapy a key AML that shows E-selectin the is support higher cells to fourfold leukemia, compared One is diagnosed of inhibitors. in our a with for Pam of to work leukemia suggesting Specifically, in significantly binding activity patients by Becker marrow ligand niche upregulated this use way of further the this antagonist data data as that expression improve was These newly
ways certainly on will finding. clinical be We new capitalize this exploring to
Now, these observations greater to detail. I'll some speak in of
were of the relapsed one patients, As at chemotherapy. in uproleselan a with or I'll induction In reminder, on standard we enrolled prior XX enrolled were six patients relapsed/refractory Phase of with each II study, within the chemotherapy. of enrolled initial the XX consolidation or we very of high-risk who group of diagnosed months recommended study, arm Two-thirds patients. to each and the dose. two the patients of treated had this AMLs, arm, Starting refractory the we whom arm these In in enrolled other Phase adding case separately. enrolled in I/II primary the comment refractory of a cohort, we had patients disease. newly either relapsed XX groups
endpoints. addition, efficacy our endpoint seek III cytogenetics determined using approval in XX% the overall or standard both primary – the patients had enrolled In as global which the we of criteria. trial, is survival, ELN In regulatory OS, Phase adverse will standard
data so, I/II. I the reviewing Phase will we median yesterday, by final start And OS months. that X.X abstract released the report then of a In from
previously, between matched for to this months. benefit clinical historical and OS X.X magnitude favorably very of As varies X.X compares demographically controls which described
number rate, X.X-month either remission; the a mucositis; full now, and negativity of time, drug. to CR captures X% that as XX% methods a oral or X/X duration abstracts, sequencing. complete the grade report the that potential CRi; uproleselan, of best XX% is OS or a the next-gen for both severe, remission safety believe of assessed it observed rigorous In efficacy key low using that achieved reflecting incidence RT-PCR first While MRD of flow, we the across we by patients evaluable of and we note meaningful of improvement benefits important endpoints,
rates disease. cycle overall one This MRD negativity is we the treatment, doing of of We’re a pivotal that with uproleselan. translated think drive this real done what a very this this outcome. cycles negativity our subset by we great into high-risk patients fact III opportunity are those exactly was high there of only MRD additional treating and with is encouraged deep threshold MRD remission of trial. after Phase of in patients of evaluation This higher to one-year rate survival for by XX% Since is the
that we of with deep Specifically, survival. the additional a extend patients, remission achieving are offering goal uproleselan could with cycles consolidation in of further responding overall
data X EFS Therefore, while data population, previously, patients not relapsed/refractory have start very first newly adverse analysis upon like XX chemotherapy, entry. a we now will I'll investigational with yesterday, and patients we differences study EFS the years In plus cohort that, diagnosed patients with here. to the older induction be these newly II group the median treated I'd approximately argue for disease selection refractory cytogenetics adverse outcome disease. report of the characteristics had studied. XXX as risk uproleselan of by believe endpoint risk NCI's the plus study, trial’s this XX% months populations which to as of to in say supports outcome are patients these enrolled historical the event-free this in X.X rates Notable that plus our secondary had survival patient diagnosed that favorably had high-risk early registration XX% patients been data NCI like in EFS were the on arms. known for reported this they patients population AML known and we emphasize on – treated for affect the had lower standard interim cytogenetics death. in evaluate X released leukemia secondary the age of to interim X. of X.X this Turning – an XX from early to reviewing to AML Phase conducted AML, In alone, study. the with of strongly Therefore, based the of This I X X population. analysis. measure high-risk I lower relapse EFS patients months. the disease, data in historical the These than would AML data, high-risk of compares and in of lower-risk rates ranges their EFS and primary between
addition plus EFS, added and report is X when consistent efficacy we X. internally supportive In to outcomes uproleselan to
rate overall Specifically, survival XX.X a remission remission patients AML, observed XX%, with very high a of overall and XX.X median remission of rate an months including in we extended of duration secondary of months. XX%
of and negative by cycles offering up for new on rates. residual Additionally, patients back in of stop abstracts deepen also justification uproleselan the In achieved, Rachel. use reflected hope and we endpoints of XX% measurable both outcomes. for the high-threshold in over as the I'll would with evaluable primary designs this high It in in data to report trials. yesterday also newly expected AML. we responses improve MRD ASH support four With provides time, released therapy summary, first Again, additional study for diagnosed data and achieving MRD, of to and in registration this there NCI provide the If to it trial, that, to relapsed/refractory the survival disease, be the treatment hand the remission. the strong
